WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Muntaha Abdullah Rashid, Khalid Abdullah Al-Khazraji

ABSTRACT

Background: Pancreatic cancer ranks 11th in women and 12th in men worldwide. Pancreatic cancer patients often have diabetes, which is a risk factor and early symptom. Numerous research have examined the link between diabetes and pancreatic cancer. Diabetes' predictive influence on pancreatic cancer patients' long-term survival is examined. Patients and method: A retrospective cohort analysis of pancreatic cancer patient data at Oncology Teaching Hospital. The trial ran from May 1, 2022, until February 1, 2023. It comprised 156 histopathologically confirmed pancreatic cancer patients from January 2018 to September 2022 in two groups. The exposed group included 67 patients who had diagnosed with type 2 diabetes before pancreatic cancer, at same time or after cancer diagnosis; and the non-exposed group with no signs of diabetes. Results: This research includes 156 pancreatic cancer patients. The mean age was 56.2 ± 11.2 years. The male percentage was 88 (56.4%) and the female proportion 68 (43.6%). The most prevalent histological picture was 89.1% adenocarcinoma. The average cancer duration was 14.2 ± 9.9 months, while the average diabetes duration was 5.7 ± 3.8 years. This study indicated that the median survival time was 12 months and that diabetes did not affect survival (log-rank test = 0.71). Age (HR = 1.04, P-value <0.001), renal illness (HR=2.6, P-value = 0.01), and palliative care (HR = 7.61, P-value <0.001) increased mortality risk, but not diabetes (HR = 1.11, P-value = 0.6). Conclusion: Survival was significantly influenced by age, histopathological picture, cancer stage and treatment modality used but there was no significant effect of the presence of diabetes on the survival.

[Full Text Article] [Download Certificate]